Navigation Links
Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
Date:6/1/2011

arantus covering the shares to be issued to Generex is declared effective.  Generex management, along with the Generex Board of Directors, will evaluate the feasibility of declaring a dividend of the Amarantus shares to its stockholders should the reverse split not be effected.

The specific portion of the Amarantus stock shares to be subject of the dividend has not yet been determined by the Board of Directors, and will be subject to Delaware rules relating to impairment of capital, which may limit the number of Amarantus shares Generex may dividend to its shareholders.  In addition, Generex can make no prediction on the inherent value of the Amarantus stock and, as Amarantus has only recently become traded on the OTCBB as the result of a "reverse merger," the price of its shares may fluctuate significantly.

Commenting on the announcement, Generex President & Chief Executive Officer Mark Fletcher stated:  "Generex management sees a potential dividend of Amarantus shares to the Generex stockholders as a way of enabling them to directly benefit from our efforts to create new value from our existing assets.  We are confident that should a reverse split be approved at our annual stockholders, meeting, we will have the ability to achieve greater financial flexibility through an up-listing.  We hope this will be the first of many opportunities to create new value for our intellectual property portfolio and we intend to aggressively pursue such opportunities in the future."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is engaged in the research and development of first-in-class disease–modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular.  The Company's most advanced product candidate, MANF, is a therapeutic protein indicated for th
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
(Date:9/29/2014)... et SAN DIEGO ... Company, Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) ... aujourd,hui la conclusion d,un accord de fusion définitif ... la totalité des actions ordinaires en circulation d,Ambit ... par le biais d,une offre publique d,achat qui ...
(Date:9/29/2014)... Sept. 29, 2014  Bob Pack, who lost his ... on the California Medical Association to immediately cease airing ... the San Jose Mercury News called "shamelessly deceptive" and ... wants voters to believe about the measure is wrong." ... Prop 46 requirement that doctors check California,s ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... Computer Resources of America, Inc. ... in New York City, has been awarded a ... transform, manage, and support the IT environment of ... leading provider of innovative services that enable individuals ... The contract will cover the four NY-metro locations ...
(Date:9/30/2014)... All on Four dental implants ... have received dental implants to vigilant in the fight ... The post, which can be found at http://www.newalbanyimplants.com/dr-rons-blog/ ... don’t brush and floss diligently, they could lose their ... teeth: the bone will deteriorate and the implants will ...
(Date:9/30/2014)... Ontario, Canada (PRWEB) September 30, 2014 ... diagnostic imaging services based in San Juan, Puerto ... automate their workflows. , Nivia Souffront, site ... to their facility. “We are excited to bring ... to provide better patient care and physician satisfaction ...
(Date:9/30/2014)... Westminster, Maryland (PRWEB) September 30, 2014 3M ... of acrylic very high bond tapes. 3M 5906 , ... 3M 5909 are conformable VHBs which help create the ... acrylic foam tapes are used for bonding to difficult surfaces ... , 3M VHBs 5906, 5907, 5908, and 5905 are designed ...
(Date:9/30/2014)... Doctors often order breast ultrasounds as a ... Most breast ultrasounds are done at a specialized medical imaging ... Miami . The Center for Diagnostic Imaging is now ... Most patients find ultrasounds to be more comfortable as ... have to remain perfectly still. , “We realize ...
Breaking Medicine News(10 mins):Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Signet Puerto Rico Leverages PowerServer RIS/PACS/PM™ to Improve Patient Care, Cut Costs 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Breast Ultrasounds Are a Comfortable and Convenient Option for Patients and Referring Doctors 2
... help medicine go down , , ... medicine go down" -- parents know in reality it just isn,t ... -- unique, frozen single-use packages that offer cooling, soothing relief to ... , Sucrets ICE is the newest member ...
... the definitive online resource for women who want to look fabulous ... Zuckerbrot, M.S., R.D., has assembled the most credited team of experts ... them all together on one website to offer the most on-trend, ... no cost and no calories to the consumer. , ...
... first 3 months more likely to have respiratory woes , , ... folic acid (folate) during early pregnancy may have an increased ... Folate is recommended to reduce the risk of birth defects, ... The researchers examined data on more than 32,000 children born ...
... behavior and screening have contributed greatly to the 13 percent ... playing a supporting role, according to new research from David ... first to report a long-term decline in cancer mortality, Cutler,s ... decline. Published in the fall edition of the Journal ...
... News/ -- EIN News has announced the launch of a new ... , With new advances in medicine, more and ... key components to surviving cancer. , ... about prostate cancer, its risk factors, screening procedures and drugs to ...
... Southern Research Institute -- a not-for-profit scientific organization that conducts ... discovery and development, advanced engineering, environmental and energy production -- ... Black & Veatch to help support the U.S. Department of ... , The award is expected ...
Cached Medicine News:Health News:New Sucrets(R) ICE Cools Sore Throat Pain 2Health News:SkinnyAndTheCity.com Top Experts Create the Ultimate Lifestyle Guide 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2Health News:Drop in cancer deaths tied primarily to gains in behavior and screening 2Health News:EIN News Introduces 'Prostate Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: